# CardiAMP™ Cell Therapy for Heart Failure Trial

Study · id `cardio:ct-nct02438306` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02438306](<https://clinicaltrials.gov/study/NCT02438306>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02438306

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 125 participants.

## Technical summary

Registry record NCT02438306. Randomized; double masking; primary purpose treatment. Start 2016-12 (actual); primary completion 2025-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 125 participants (enrolled count; ClinicalTrials.gov record NCT02438306, source copy `cardio:ctgov-nct02438306-2025-09-19`, retrieved 2026-10-26)
- Started: 2016-12 (actual) (ClinicalTrials.gov record NCT02438306, source copy `cardio:ctgov-nct02438306-2025-09-19`, retrieved 2026-10-26)
- Primary completion: 2025-02 (actual) (ClinicalTrials.gov record NCT02438306, source copy `cardio:ctgov-nct02438306-2025-09-19`, retrieved 2026-10-26)
- Completion: 2025-06 (actual) (ClinicalTrials.gov record NCT02438306, source copy `cardio:ctgov-nct02438306-2025-09-19`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT02438306, source copy `cardio:ctgov-nct02438306-2025-09-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02438306-2025-09-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: CardiAMP™ Cell Therapy for Heart Failure Trial
- Condition: Heart Failure, Systolic
- Intervention (Biological): Autologous cell therapy
- Intervention (Other): Sham
- Lead sponsor: BioCardia, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)

## Provenance

Content hash: deebe89f51f47e656336a6e8c1503c5663eadee7992433b5a78c69e6f909ba67
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
